Inhaled tigecycline treatment for lung infections caused by Mycobacterium abscessus
Inhaled tigecycline therapy for pulmonary M. abscessus infections
This study is looking at a new way to use an antibiotic called tigecycline to help people with chronic lung infections from Mycobacterium abscessus, especially those who already have lung issues like cystic fibrosis, by making it easier to inhale the medicine directly into the lungs for better results and fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Colorado State University NIH-funded |
| Lab location | 1 site (Fort Collins, United States) |
| Project ID | NIH-11086118 on NIH RePORTER |
What this research studies
This research investigates the use of inhaled tigecycline, an antibiotic, to treat chronic lung infections caused by Mycobacterium abscessus, particularly in patients with pre-existing lung conditions like cystic fibrosis. The study aims to develop a formulation that allows for easy inhalation, improving the drug's effectiveness while minimizing side effects associated with intravenous administration. By delivering the medication directly to the lungs, the researchers hope to enhance its therapeutic potential and reduce the burden of antibiotic resistance. The approach is based on preliminary studies showing promising results in animal models.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with chronic pulmonary infections caused by Mycobacterium abscessus, especially those with underlying lung diseases.
Not a fit: Patients without chronic lung infections or those who do not have pre-existing lung conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and better-tolerated treatment option for patients suffering from chronic pulmonary infections.
How similar studies have performed: Preliminary studies have shown success with similar inhalation approaches in animal models, indicating potential for effective treatment in humans.
Where this research is happening
Fort Collins, United States
- Colorado State University — Fort Collins, United States (Active)
Researchers
- Principal investigator: Gonzalez-Juarrero, Mercedes — Colorado State University
- Study coordinator: Gonzalez-Juarrero, Mercedes
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.